Filtered By:
Specialty: Nutrition
Drug: SGLT2 Inhibitors
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Novel antidiabetic drugs and cardiovascular risk: primum non nocere
Conclusions Results of safety outcome studies focused on CV events, including HF and mortality for CV causes, are not homogeneous. A critical analysis of these studies may help cardiologists and diabetes specialists to adapt their therapeutic choices to individual patients.
Source: Nutrition, Metabolism and Cardiovascular Diseases - June 15, 2016 Category: Nutrition Source Type: research
